Foley Trasimene Acquisition Corp.: “There are so many of these things that it’s very difficult to keep track of, and I don’t want you in them. We’re done with that era. I think we’ve got to let these stocks come down … It’s too darn hard for investors.”
Peloton: “It’s had a big run and I’m moving on.”
Tellurian: “It’s a terrific $2 spec. I call it a call option. It’s almost a lottery ticket, but I don’t like betting against [co-founder] Charif Souki.”
Palantir: “I don’t think this is the time to double down … You don’t double down until something has come down significantly enough to change your [cost] basis.”
G1 Therapeutics: “These are stocks that I never say no to anyone, provided they recognize that it’s the speculative stock in their portfolio. It is not like owning a Merck.”